Laura Korin: STARGLO Shows Sustained Survival Benefit with Glofitamab-GemOx in DLBCL
Laura Korin/X

Laura Korin: STARGLO Shows Sustained Survival Benefit with Glofitamab-GemOx in DLBCL

Laura Korin, physician in the Hematology Service and Hematopoietic Transplantation Unit at the Alexander Fleming Institute, shared on X:

“A knockout win for glofitamab-GemOx vs R-GemOx in ASCT-ineligible R/R DLBCL!

  • 4-year OS: 45.5% vs 27.1%
  • CRR: 57.9% vs 23.1%
  • Median DOCR: Not reached vs 18.9 months
  • 3-year DOCR: 60.2% vs 48.8%

A new benchmark for future control arms.”

Laura Korin: STARGLO Shows Sustained Survival Benefit with Glofitamab-GemOx in DLBCL